You just read:

Maxwell Biotech Venture Fund's Portfolio Company Hepatera Announces Start of Second Phase 2 Clinical Trial of Myrcludex B in Chronic Hepatitis B/D Infection

News provided by

Maxwell Biotech Venture Fund

May 25, 2016, 08:00 ET